Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Moderna, Inc. MRNA
$128.20
-$0.21 (-0.17%)
На 18:01, 12 мая 2023
+52.64%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
48546965131.00000000
-
week52high
217.25
-
week52low
115.03
-
Revenue
19263000000
-
P/E TTM
6
-
Beta
1.69698900
-
EPS
19.70000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Underperform | Underperform | 04 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 авг 2022 г. |
| SVB Leerink | Underperform | Underperform | 01 авг 2022 г. |
| SVB Leerink | Underperform | Underperform | 07 июн 2022 г. |
| Piper Sandler | Overweight | Overweight | 18 мая 2022 г. |
| Argus Research | Buy | Buy | 14 сент 2022 г. |
| Deutsche Bank | Buy | Hold | 08 сент 2022 г. |
| JP Morgan | Neutral | Neutral | 24 окт 2022 г. |
| SVB Leerink | Market Perform | Underperform | 21 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 18 окт 2022 г. |
| Goldman Sachs | Buy | Buy | 13 окт 2022 г. |
| Chardan Capital | Buy | Buy | 07 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 20 дек 2022 г. |
| Jefferies | Buy | Hold | 19 дек 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 16 дек 2022 г. |
| Chardan Capital | Neutral | Buy | 14 дек 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 18 янв 2023 г. |
| Chardan Capital | Neutral | Neutral | 18 янв 2023 г. |
| Cowen & Co. | Market Perform | Market Perform | 25 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bancel Stephane | D | 1627155 | 40000 | 02 февр 2023 г. |
| Bancel Stephane | D | 5411946 | 1449 | 02 февр 2023 г. |
| Bancel Stephane | D | 5413395 | 15790 | 02 февр 2023 г. |
| Bancel Stephane | D | 5429185 | 10263 | 02 февр 2023 г. |
| Bancel Stephane | D | 5439448 | 8908 | 02 февр 2023 г. |
| Bancel Stephane | D | 5448356 | 1589 | 02 февр 2023 г. |
| Bancel Stephane | D | 5449945 | 2001 | 02 февр 2023 г. |
| Bancel Stephane | A | 5451946 | 40000 | 02 февр 2023 г. |
| Bancel Stephane | D | 1667155 | 40000 | 01 февр 2023 г. |
| Bancel Stephane | D | 5411946 | 4697 | 01 февр 2023 г. |
Новостная лента
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
The Motley Fool
11 мая 2023 г. в 14:00
Investors will love Johnson & Johnson's commitment to dividend payments. Vertex Pharmaceuticals already delivers billion-dollar earnings -- and new programs could further lift growth.
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
The Motley Fool
11 мая 2023 г. в 10:23
The global RSV vaccine market isn't all that big, and healthcare giants are battling for market share. Potential vaccines from Pfizer and Moderna have demonstrated high efficacy in late-stage trials.
As COVID public health emergency ends, ‘whack-a-mole' virus won't be easy to track
Market Watch
10 мая 2023 г. в 14:30
As the U.S. COVID-19 public health emergency comes to an end on Thursday, the fight against COVID goes on–-and some new challenges begin for those who hope to keep the virus at bay.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research
09 мая 2023 г. в 10:43
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market
The Motley Fool
09 мая 2023 г. в 09:16
Moderna's next big moment may come at the start of 2023's fall vaccination season. The vaccine giant's infrastructure and supply chain are ready -- and it says its discussions with commercial buyers have been "positive.